Belgian probe into 'anti-competitive' pharma companies

25 November 2016

The Belgian Competition Authority (BCA) has confirmed that it is inspecting several companies involved in the wholesale distribution of pharmaceutical and para-pharmaceuticals products to pharmacies.

These inspections at companies’ premises stem from information which the BCA has about possible infringements of European Union law, in particular of alleged participation in anti-competitive agreements or concerted practices between wholesalers active in Belgium, relating to the services they provide to pharmaceutical laboratories and to pharmacies.

The BCA has stressed that these investigations are a preliminary step in the investigation of restrictive practices and that the companies involved will have the right to defend themselves in the course of proceedings.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK